Status:

COMPLETED

Wearable Diagnostic for Detection of COVID-19 Infection

Lead Sponsor:

ClinOne, Inc.

Collaborating Sponsors:

BioIntelliSense, Inc

Phillips North America, LLC

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Brief Summary

The goals of this study are 1) to validate the use of a wearable diagnostic capability and software as a medical device (SaMD) algorithm for the pre or early-symptomatic detection of COVID-19 infectio...

Detailed Description

This is an open label iterative study designed to calibrate the algorithm to maximize its test characteristics. The sample size is derived from the minimum number of COVID-19 subjects required to eval...

Eligibility Criteria

Inclusion

  • Cohort 1- Exposed/ Early Symptomatic Group
  • age 18 or older;
  • able to follow the study device wear instructions per the Instructions for Use;
  • no positive viral test within 60 days prior to enrollment; and
  • willing and able to provide written, informed consent.

Exclusion

  • pregnant or breastfeeding;
  • wearing a defibrillator or pacemaker;
  • known or suspected cardiac dysrhythmias
  • known or suspected allergy to adhesives;
  • chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  • open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  • current or planned use of either an investigation pharmaceutical or an investigational device during the study.
  • Cohort 1- Vaccine Group
  • Inclusion Criteria:
  • Subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series are eligible for the study if they are:
  • Age 18 or older; 12 years of age -17 years of age are approved to participate in the vaccine Cohort portion of the study.
  • scheduled to receive their first and second dose of the Pfizer/BioNTech or Moderna COVID-19 vaccine
  • able to follow the study device wear instructions per the Instructions for Use;
  • no positive viral test within 60 days prior to enrollment; and
  • willing and able to provide written, informed consent.
  • Willing and able to take an oral temperature

Key Trial Info

Start Date :

December 21 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 15 2022

Estimated Enrollment :

790 Patients enrolled

Trial Details

Trial ID

NCT04742569

Start Date

December 21 2020

End Date

January 15 2022

Last Update

January 20 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ClinOne, Inc

Greenwood Village, Colorado, United States, 80111